GeneOne Life Science, Inc. (KRX:011000)

South Korea flag South Korea · Delayed Price · Currency is KRW
2,460.00
+120.00 (5.13%)
At close: Sep 5, 2025
5.13%
Market Cap208.38B
Revenue (ttm)34.71B
Net Income (ttm)-50.50B
Shares Out84.71M
EPS (ttm)-1,000.26
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,383,702
Average Volume710,862
Open2,340.00
Previous Close2,340.00
Day's Range2,340.00 - 2,685.00
52-Week Range1,830.00 - 4,270.00
Beta0.57
RSI61.70
Earnings DateAug 14, 2025

About GeneOne Life Science

GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1976
Employees 41
Stock Exchange Korea Stock Exchange
Ticker Symbol 011000
Full Company Profile

Financial Performance

In 2024, GeneOne Life Science's revenue was 35.72 billion, a decrease of -11.15% compared to the previous year's 40.20 billion. Losses were -48.54 billion, -37.59% less than in 2023.

Financial Statements

News

There is no news available yet.